Pharmaceutical intermediates
Finerenone Intermediates
6 pharmaceutical intermediates for Finerenone. Indication: Chronic Renal Insufficiency.
About Finerenone
- Originator
- Bayer Healthcare Pharmaceuticals Inc
- Indication
- Chronic Renal Insufficiency
- Approved Date
- 07/09/2021
- NCE Patent
- 07/09/2026
- DS/DP
- 04/12/2029
Available intermediates
6 intermediates currently listed for Finerenone. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Bromo-2-methoxybenzaldehyde | 43192-33-2 | / | / |
| 4-formyl-3-methoxybenzonitrile | 21962-45-8 | / | / |
| 4-AMino-5-Methylpyridin-2-ol | 95306-64-2 | / | / |
| 2-chloro-5-methylpyridin-4-amine | 79055-62-2 | / | / |
| 2-Cyanoethyl 3-oxobutanoate | 65193-87-5 | / | / |
| 2-cyanoethyl 4-(4-cyano-2-methoxyphenyl)-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthyridine-3-carboxylate | 1050477-43-4 | / | / |
Building toward Finerenone?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →